Author: Tronserve admin
Monday 2nd August 2021 10:48 AM
Korean Biotech Firms Rush To Embrace Liquid Biopsy for Personalized Medicine
Korean biotech companies are rushing to commercialize DNA-based liquid biopsy market, gaining fast recognition as personalized medicine to enable early cancer detection, prognostic assessment, and more precise treatment. The global cancer diagnostics market size was valued at $23.49 million in 2016 and is expected to grow to $2.39 billion in 2030, according to Grand View Research, Inc.
Macrogen Inc., a Korean precision medicine and biotechnology company, launched a commercial liquid biopsy service named ‘axen’ developed as part of a state project in the first half of this year. The service is to diagnose a potential tumor or to monitor progression with a blood sample from a patient that contains DNA shed from tumors, called circulating tumor DNA (ctDNA). The use of liquid biopsy in early cancer detection can help prevent cancer and save expenses, the company said.
Eone Diagnomics Genome Center Co. (EDGC) is evaluating its liquid biopsy technology in a clinical trial, which was developed to increase testing sensitivity by measuring DNA changes in a very small amount of ctDNA in a blood sample. It aims to commercialize the service in the first half of next year. Liquid biopsy can detect stage 3-4 cancer with accuracy, but detection of early stage cancer is relatively low, the company said, adding it is focusing on liquid biopsy technology for early cancer detection. Liquid biopsy for companion diagnostics is also playing an increasing role in optimizing treatment for individual cancer patients.
In May, Panagene Inc. launched PANAMutyper EGFR V2 to help select individualized cancer treatment for lung cancer patients. The new service with increased sensitivity and specificity for the detection of pathogens can detect 46 epidermal growth factor receptor (EGFR) mutants known to be involved in non-small cell lung cancer progression. It is used to identify an optimal cancer therapy for patients with stage 2 or advanced lung cancer.